Interleukin-2 treatment-associated eosinophilia is mediated by interleukin-5 production.

  title={Interleukin-2 treatment-associated eosinophilia is mediated by interleukin-5 production.},
  author={Donald H. C. Macdonald and A A Gordon and Hiroko Kajitani and H Enokihara and A. J. Barrett},
  journal={British journal of haematology},
  volume={76 2},
During a trial using recombinant human interleukin-2 (rhIL-2) immunotherapy for acute myeloblastic leukaemia (AML) in remission, eosinophilia was observed in all patients. We used in-vitro clonogenic assays to investigate the mechanism of the eosinophilia in five patients. The mean eosinophil count increased from 0.05 x 10(9)/l before rhIL-2 to 0.98 x 10(9)/l within 48 h of stopping the infusion, and an exponential correlation between the pretreatment lymphocyte CD4:CD8 ratio and the maximum… CONTINUE READING
Highly Cited
This paper has 27 citations. REVIEW CITATIONS


Publications citing this paper.
Showing 1-10 of 16 extracted citations

Cytokines in Human Health

Methods in Pharmacology and Toxicology • 2007

Similar Papers

Loading similar papers…